Table 1. Demographic profiles in patients with schizophrenia and controls (Mean ± SD).
| Variables | Association between rs429358 and schizophrenia | Association between rs429358 and cognition score | ||||||
| Cases (n = 637) | Controls (n = 467) | t/X2 | P value | Cases (n = 415) | Controls (n = 400) | t/X2 | P value | |
| Age (year) | 47.52 ± 10.61 | 44.94 ± 13.63 | −3.392 | 0.001 | 48.19 ± 9.25 | 45.84 ± 13.37 | −2.867 | 0.004 |
| Sex | ||||||||
| Female (%) | 156 (24.5) | 274 (58.7) | 132.406 | <0.001 | 73 (17.6) | 230 (57.5) | 138.902 | <0.001 |
| Male (%) | 481 (75.5) | 193 (41.3) | 342 (82.4) | 170 (42.5) | ||||
| Year of education | 9.30 ± 6.81 | 9.66 ± 5.33 | 0.955 | 0.340 | 9.19 ± 6.77 | 9.40 ± 5.59 | 0.473 | 0.636 |
| Body mass index | 24.45 ± 4.00 | 25.14 ± 4.18 | 2.538 | 0.011 | 24.68 ± 3.89 | 25.41 ± 4.14 | 2.378 | 0.018 |
| Age of onset | 23.20 ± 5.16 | – | – | – | 23.12 ± 4.67 | – | – | – |
| Illness of course (year) | 24.43 ± 10.52 | – | – | – | 25.23 ± 9.49 | – | – | – |
| Mean daily dose (mg/day) (chlorpromazine equivalents) | 391.72 ± 181.22 | – | – | – | 388.78 ± 171.19 | – | – | – |
| ApoA1 level (g/L) | 1.53 ± 0.38 | – | – | – | 1.50 ± 0.38 | – | – | – |
| ApoB level (g/L) | 0.89 ± 0.24 | – | – | – | 0.88 ± 0.25 | – | – | – |
| RBANS Total score | – | – | – | – | 64.60 ±15.66 | 80.04 ± 15.12 | 14.308 | <0.001 |
| Immediate memory score | – | – | – | – | 58.68 ± 16.82 | 75.69 ± 17.31 | 14.219 | <0.001 |
| Attention score | – | – | – | – | 71.56 ± 18.13 | 87.44 ± 20.35 | 11.767 | <0.001 |
| Language score | – | – | – | – | 81.06 ± 15.45 | 93.89 ± 13.09 | 12.810 | <0.001 |
| Visuospatial/Constructional score | – | – | – | – | 78.00 ± 19.45 | 79.62 ± 15.59 | 1.313 | 0.190 |
| Delayed memory score | – | – | – | – | 66.24 ± 19.27 | 86.25 ± 15.26 | 16.465 | <0.001 |